CPT code 0655T denotes a transperineal, image-guided laser ablation procedure for malignant prostate tissue that incorporates enhanced imaging such as MR–fused ultrasound. This emerging, incision-sparing intervention matters nationally as it reflects growing use of targeted, image-guided focal therapies in prostate cancer management and potential impacts on surgical volume, imaging utilization, and ambulatory procedure adoption. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what CPT code 0655T covers, the clinical context of transperineal laser ablation with MR–fused imaging, and typical sites where the procedure is performed. The publication summarizes expected billing considerations and common modifiers (listed separately), outlines payer coverage presence, and highlights benchmarks and policy topics relevant to adoption and reimbursement. The content is intended to help stakeholders understand the code’s scope, clinical role in prostate cancer care, and where to look for payer guidance and utilization trends. Data not available in the input is noted where applicable.